Kiniksa Pharmaceuticals International’s consensus price target was modestly raised to $47.00 on the back of strong commercial execution, robust launch momentum, and continued outperformance, reflecting optimism on deeper penetration and expansion opportunities.
Analyst Commentary
- Strong commercial execution driving revenue outperformance.
- Robust growth across all product launch metrics.
- Ongoing "beat & raise" performance indicating consistent operational overachievement.
- Opportunity for deeper penetration into current target populations.
- Potential for expansion into a broader patient population, presenting further upside.
What's in the News
- Raised 2025 net product revenue guidance to $625–$640 million, up from prior range of $590–$605 million.
Valuation Changes
Summary of Valuation Changes for Kiniksa Pharmaceuticals International
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $46.50 to $47.00.
- The Future P/E for Kiniksa Pharmaceuticals International has fallen slightly from 24.22x to 23.02x.
- The Consensus Revenue Growth forecasts for Kiniksa Pharmaceuticals International has risen slightly from 23.3% per annum to 24.3% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.